PDUFA: March 31 – Invokana
The US Food and Drug advisory panel has voted for the preliminary approval of Invokana (canagliflozin), Johnson and Johnson’s new type 2 diabetes drug, in […]
johnson and johnson
Dendreon: Anticancer Immunotherapy, Reimbursement, and New Promises
This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.